Chemokines and microRNAs in atherosclerosis

Cellular and Molecular Life Sciences

Volumn 72, Issue 17, 2015, Pages 3253-3266

  Hartmann, Petra ^a   Schober, Andreas ^a   Weber, Christian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Chemokines; Inflammation; MicroRNAs

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR CXCR7; CXCL1 CHEMOKINE; CXCL16 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICRORNA; MICRORNA 103; MICRORNA 10A; MICRORNA 126; MICRORNA 126 3P; MICRORNA 155; MICRORNA 181B; MICRORNA 21; MICRORNA 24; MICRORNA 342 5P; MICRORNA 467B; MICRORNA 92A; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOGENESIS; DISEASE COURSE; DRUG TARGETING; ENDOTHELIUM CELL; GENE SILENCING; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REVIEW; SMOOTH MUSCLE FIBER; VASCULITIS; BIOLOGICAL MODEL; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; CHEMOKINES; ENDOTHELIAL CELLS; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; MACROPHAGES; MICRORNAS; MODELS, BIOLOGICAL; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION;

EID: 84938995114     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-015-1925-z     Document Type: Review

References (109)

1. Zernecke A, Weber C (2014) Chemokines in atherosclerosis: proceedings resumed. Arterioscler Thromb Vasc Biol 34(4):742-750. doi: 10.1161/ATVBAHA.113.301655
2. Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787-820. doi: 10.1146/annurev.immunol.24.021605.090529
3. Nazari-Jahantigh M, Egea V, Schober A, Weber C (2014) MicroRNA-specific regulatory mechanisms in atherosclerosis. J Mol Cell Cardiol. doi: 10.1016/j.yjmcc.2014.10.021
4. Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A (2013) MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol 33(3):449-454. doi: 10.1161/ATVBAHA.112.300279
5. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A (2014) International Union of Basic and Clinical Pharmacology [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 66(1):1-79. doi: 10.1124/pr.113.007724
6. Zlotnik A, Yoshie O (2012) The chemokine superfamily revisited. Immunity 36(5):705-716. doi: 10.1016/j.immuni.2012.05.008
7. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, Mayo KH, Weber C (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 15(1):97-103. doi: 10.1038/nm.1898
8. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, Hackeng TM, Weber C (2005) Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 105(3):924-930. doi: 10.1182/blood-2004-06-2475
9. Rajarathnam K, Sykes BD, Kay CM, Dewald B, Geiser T, Baggiolini M, Clark-Lewis I (1994) Neutrophil activation by monomeric interleukin-8. Science 264(5155):90-92
10. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 100(4):1885-1890. doi: 10.1073/pnas.0334864100
11. Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, Mulkins M, Bhakta S, McCarley D, Wiesent L, Wong B, Jarnagin K, Handel TM (1998) Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J Biol Chem 273(50):33157-33165
12. Ravindran A, Sawant KV, Sarmiento J, Navarro J, Rajarathnam K (2013) Chemokine CXCL1 dimer is a potent agonist for the CXCR2 receptor. J Biol Chem 288(17):12244-12252. doi: 10.1074/jbc.M112.443762
13. Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM (2009) Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol 183(5):3425-3432. doi: 10.4049/jimmunol.0900305
14. Vives RR, Sadir R, Imberty A, Rencurosi A, Lortat-Jacob H (2002) A kinetics and modeling study of RANTES(9-68) binding to heparin reveals a mechanism of cooperative oligomerization. Biochemistry 41(50):14779-14789
15. Baltus T, Weber KS, Johnson Z, Proudfoot AE, Weber C (2003) Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood 102(6):1985-1988. doi: 10.1182/blood-2003-04-1175
16. Das ST, Rajagopalan L, Guerrero-Plata A, Sai J, Richmond A, Garofalo RP, Rajarathnam K (2010) Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment. PLoS ONE 5(7):e11754. doi: 10.1371/journal.pone.0011754
17. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, Wells TN (1997) Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36(44):13570-13578. doi: 10.1021/bi971125s
18. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F (2008) A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 28(6):1090-1096. doi: 10.1161/ATVBAHA.108.165423
19. Murooka TT, Wong MM, Rahbar R, Majchrzak-Kita B, Proudfoot AE, Fish EN (2006) CCL5-CCR5-mediated apoptosis in T cells: requirement for glycosaminoglycan binding and CCL5 aggregation. J Biol Chem 281(35):25184-25194. doi: 10.1074/jbc.M603912200
20. Doring Y, Pawig L, Weber C, Noels H (2014) The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol 5:212. doi: 10.3389/fphys.2014.00212
21. Moser B, Willimann K (2004) Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis 63 Suppl 2:ii84-ii89. doi: 10.1136/ard.2004.028316
22. Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW, Gerzsten RE, Edelman ER, Jain MK (2007) Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem 282(18):13769-13779. doi: 10.1074/jbc.M700078200
23. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI (2000) The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA 97(16):9052-9057
24. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, Polykratis A, Kollias G, de Winther MP, Pasparakis M (2008) Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab 8(5):372-383. doi: 10.1016/j.cmet.2008.08.016
25. Mehrad B, Keane MP, Strieter RM (2007) Chemokines as mediators of angiogenesis. Thromb Haemost 97(5):755-762
26. Berahovich RD, Zabel BA, Penfold ME, Lewen S, Wang Y, Miao Z, Gan L, Pereda J, Dias J, Slukvin II, McGrath KE, Jaen JC, Schall TJ (2010) CXCR7 protein is not expressed on human or mouse leukocytes. J Immunol 185(9):5130-5139. doi: 10.4049/jimmunol.1001660
27. Viola A, Luster AD (2008) Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48:171-197. doi: 10.1146/annurev.pharmtox.48.121806.154841
28. Fox JM, Letellier E, Oliphant CJ, Signoret N (2011) TLR2-dependent pathway of heterologous down-modulation for the CC chemokine receptors 1, 2, and 5 in human blood monocytes. Blood 117(6):1851-1860. doi: 10.1182/blood-2010-05-287474
29. Curnock AP, Logan MK, Ward SG (2002) Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 105(2):125-136
30. Novitzky-Basso I, Rot A (2012) Duffy antigen receptor for chemokines and its involvement in patterning and control of inflammatory chemokines. Front Immunol 3:266. doi: 10.3389/fimmu.2012.00266
31. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z (2008) Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117(13):1649-1657. doi: 10.1161/CIRCULATIONAHA.107.745091
32. Weber KS, von Hundelshausen P, Clark-Lewis I, Weber PC, Weber C (1999) Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol 29(2):700-712. doi: 10.1002/(SICI)1521-4141(199902)29:02<700:AID-IMMU700>3.0.CO;2-1
33. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K (2001) The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 108(9):1307-1314. doi: 10.1172/JCI12877
34. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, Heyll K, Chun J, Saulnier-Blache JS, Reinholz M, van Zandvoort M, Weber C, Schober A (2011) Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab 13(5):592-600. doi: 10.1016/j.cmet.2011.02.016
35. Gautier EL, Jakubzick C, Randolph GJ (2009) Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 29(10):1412-1418. doi: 10.1161/ATVBAHA.108.180505
36. Soehnlein O, Drechsler M, Doring Y, Lievens D, Hartwig H, Kemmerich K, Ortega-Gomez A, Mandl M, Vijayan S, Projahn D, Garlichs CD, Koenen RR, Hristov M, Lutgens E, Zernecke A, Weber C (2013) Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med 5(3):471-481. doi: 10.1002/emmm.201201717
37. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, Mack M, Charo IF (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 117(4):902-909. doi: 10.1172/JCI29919
38. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C (2005) Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 25(7):1512-1518. doi: 10.1161/01.ATV.0000170133.43608.37
39. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, Swirski FK (2013) Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 19(9):1166-1172. doi: 10.1038/nm.3258
40. Postea O, Vasina EM, Cauwenberghs S, Projahn D, Liehn EA, Lievens D, Theelen W, Kramp BK, Butoi ED, Soehnlein O, Heemskerk JW, Ludwig A, Weber C, Koenen RR (2012) Contribution of platelet CX(3)CR1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia. Arterioscler Thromb Vasc Biol 32(5):1186-1193. doi: 10.1161/ATVBAHA.111.243485
41. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung S (2009) CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 113(4):963-972. doi: 10.1182/blood-2008-07-170787
42. Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17(11):1410-1422. doi: 10.1038/nm.2538
43. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, Weber C, Schober A (2012) MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 122(11):4190-4202. doi: 10.1172/JCI61716
44. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340(2):115-126. doi: 10.1056/NEJM199901143400207
45. Akhtar S, Gremse F, Kiessling F, Weber C, Schober A (2013) CXCL12 promotes the stabilization of atherosclerotic lesions mediated by smooth muscle progenitor cells in Apoe-deficient mice. Arterioscler Thromb Vasc Biol 33(4):679-686. doi: 10.1161/ATVBAHA.112.301162
46. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92-105. doi: 10.1101/gr.082701.108
47. Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15(8):509-524. doi: 10.1038/nrm3838
48. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RT, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, Weber C (2014) MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 20(4):368-376. doi: 10.1038/nm.3487
49. Helwak A, Kudla G, Dudnakova T, Tollervey D (2013) Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153(3):654-665. doi: 10.1016/j.cell.2013.03.043
50. Oynebraten I, Bakke O, Brandtzaeg P, Johansen FE, Haraldsen G (2004) Rapid chemokine secretion from endothelial cells originates from 2 distinct compartments. Blood 104(2):314-320. doi: 10.1182/blood-2003-08-2891
51. Schwartz D, Andalibi A, Chaverri-Almada L, Berliner JA, Kirchgessner T, Fang ZT, Tekamp-Olson P, Lusis AJ, Gallegos C, Fogelman AM et al (1994) Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest 94(5):1968-1973. doi: 10.1172/JCI117548
52. Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, Terkeltaub RA (2006) Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol 168(4):1385-1395
53. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC (2007) Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100(8):1164-1173. doi: 10.1161/01.RES.0000265065.26744.17
54. Loyer X, Potteaux S, Vion AC, Guerin CL, Boulkroun S, Rautou PE, Ramkhelawon B, Esposito B, Dalloz M, Paul JL, Julia PL, Maccario J, Boulanger CM, Mallat Z, Tedgui A (2013) Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. doi: 10.1161/CIRCRESAHA.114.302213
55. Fang Y, Davies PF (2012) Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol 32(4):979-987. doi: 10.1161/ATVBAHA.111.244053
56. Lingrel JB, Pilcher-Roberts R, Basford JE, Manoharan P, Neumann J, Konaniah ES, Srinivasan R, Bogdanov VY, Hui DY (2012) Myeloid-specific Kruppel-like factor 2 inactivation increases macrophage and neutrophil adhesion and promotes atherosclerosis. Circ Res 110(10):1294-1302. doi: 10.1161/CIRCRESAHA.112.267310
57. Manoharan P, Basford JE, Pilcher-Roberts R, Neumann J, Hui DY, Lingrel JB (2014) Reduced levels of microRNAs miR-124a and miR-150 are associated with increased proinflammatory mediator expression in Kruppel-like factor 2 (KLF2)-deficient macrophages. J Biol Chem 289(45):31638-31646. doi: 10.1074/jbc.M114.579763
58. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, Hunninghake GM, Vera MP, Blackwell TS, Baron RM, Feinberg MW (2012) MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest 122(6):1973-1990. doi: 10.1172/JCI61495
59. Sun X, He S, Wara AK, Icli B, Shvartz E, Tesmenitsky Y, Belkin N, Li D, Blackwell TS, Sukhova GK, Croce K, Feinberg MW (2014) Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 114(1):32-40. doi: 10.1161/CIRCRESAHA.113.302089
60. Son DJ, Kumar S, Takabe W, Kim CW, Ni CW, Alberts-Grill N, Jang IH, Kim S, Kim W, Won Kang S, Baker AH, Woong Seo J, Ferrara KW, Jo H (2013) The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun 4:3000. doi: 10.1038/ncomms4000
61. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD (2000) The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 86(2):131-138
62. Schober A, Karshovska E, Zernecke A, Weber C (2006) SDF-1alpha-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine? Trends Cardiovasc Med 16(4):103-108. doi: 10.1016/j.tcm.2006.01.006
63. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober A, Sperandio M, Soehnlein O, Bornemann J, Tacke F, Biessen EA, Weber C (2008) Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 102(2):209-217. doi: 10.1161/CIRCRESAHA.107.160697
64. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2(100):ra81. doi: 10.1126/scisignal.2000610
65. Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, Wenzel D, Vosen S, Franklin BS, Fleischmann BK, Nickenig G, Werner N (2013) Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 128(18):2026-2038. doi: 10.1161/CIRCULATIONAHA.113.001720
66. Noels H, Zhou B, Tilstam PV, Theelen W, Li X, Pawig L, Schmitz C, Akhtar S, Simsekyilmaz S, Shagdarsuren E, Schober A, Adams RH, Bernhagen J, Liehn EA, Doring Y, Weber C (2014) Deficiency of endothelial CXCR4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol 34(6):1209-1220. doi: 10.1161/ATVBAHA.113.302878
67. van Solingen C, de Boer HC, Bijkerk R, Monge M, van Oeveren-Rietdijk AM, Seghers L, de Vries MR, van der Veer EP, Quax PH, Rabelink TJ, van Zonneveld AJ (2011) MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1(+)/Lin(-) progenitor cells in ischaemia. Cardiovasc Res 92(3):449-455. doi: 10.1093/cvr/cvr227
68. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF (2013) miR-126 and miR-126 repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 15(3):284-294. doi: 10.1038/ncb2690
69. Schober A, Zernecke A (2007) Chemokines in vascular remodeling. Thromb Haemost 97(5):730-737
70. Schober A, Knarren S, Lietz M, Lin EA, Weber C (2003) Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 108(20):2491-2497. doi: 10.1161/01.CIR.0000099508.76665.9A
71. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, Gierschik P, Biessen EA, Weber C (2005) SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 96(7):784-791. doi: 10.1161/01.RES.0000162100.52009.38
72. Subramanian P, Karshovska E, Reinhard P, Megens RT, Zhou Z, Akhtar S, Schumann U, Li X, van Zandvoort M, Ludin C, Weber C, Schober A (2010) Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ Res 107(1):96-105. doi: 10.1161/CIRCRESAHA.109.212647
73. Karshovska E, Zagorac D, Zernecke A, Weber C, Schober A (2008) A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury. J Thromb Haemost 6(10):1812-1815. doi: 10.1111/j.1538-7836.2008.03086.x
74. Hamesch K, Subramanian P, Li X, Dembowsky K, Chevalier E, Weber C, Schober A (2012) The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. Thromb Haemost 107(2):356-368. doi: 10.1160/TH11-07-0453
75. Li X, Zhu M, Penfold ME, Koenen RR, Thiemann A, Heyll K, Akhtar S, Koyadan S, Wu Z, Gremse F, Kiessling F, van Zandvoort M, Schall TJ, Weber C, Schober A (2014) Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue. Circulation 129(11):1244-1253. doi: 10.1161/CIRCULATIONAHA.113.006840
76. Liu L, Zhao X, Zhu X, Zhong Z, Xu R, Wang Z, Cao J, Hou Y (2013) Decreased expression of miR-430 promotes the development of bladder cancer via the upregulation of CXCR7. Mol Med Rep 8(1):140-146. doi: 10.3892/mmr.2013.1477
77. Takeya M, Yoshimura T, Leonard EJ, Takahashi K (1993) Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol 24(5):534-539
78. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D (1991) Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88(12):5252-5256
79. Zhou J, Wang KC, Wu W, Subramaniam S, Shyy JY, Chiu JJ, Li JY, Chien S (2011) MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc Natl Acad Sci USA 108(25):10355-10360. doi: 10.1073/pnas.1107052108
80. Liao F, Berliner JA, Mehrabian M, Navab M, Demer LL, Lusis AJ, Fogelman AM (1991) Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest 87(6):2253-2257. doi: 10.1172/JCI115261
81. Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, Zhao Q, Nishida K, Takeshita A, Egashira K (2004) Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 24(3):534-539. doi: 10.1161/01.ATV.0000118275.60121.2b
82. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394(6696):894-897. doi: 10.1038/29788
83. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2(2):275-281
84. Schober A, Zernecke A, Liehn EA, von Hundelshausen P, Knarren S, Kuziel WA, Weber C (2004) Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res 95(11):1125-1133. doi: 10.1161/01.RES.0000149518.86865.3e
85. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, Inoue N, Hirata K, Matsukawa A, Morishita R, Kaneda Y, Yokoyama M (2002) Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol 22(1):115-120
86. Serbina NV, Pamer EG (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7(3):311-317. doi: 10.1038/ni1309
87. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF (2010) MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci USA 107(30):13450-13455. doi: 10.1073/pnas.1002120107
88. Loyer X, Potteaux S, Vion AC, Guerin CL, Boulkroun S, Rautou PE, Ramkhelawon B, Esposito B, Dalloz M, Paul JL, Julia P, Maccario J, Boulanger CM, Mallat Z, Tedgui A (2014) Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 114(3):434-443. doi: 10.1161/CIRCRESAHA.114.302213
89. Wu W, Xiao H, Laguna-Fernandez A, Villarreal G Jr, Wang KC, Geary GG, Zhang Y, Wang WC, Huang HD, Zhou J, Li YS, Chien S, Garcia-Cardena G, Shyy JY (2011) Flow-dependent regulation of Kruppel-like factor 2 is mediated by microRNA-92a. Circulation 124(5):633-641. doi: 10.1161/CIRCULATIONAHA.110.005108
90. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D, Ferrara N (2012) Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 31(17):3513-3523. doi: 10.1038/emboj.2012.183
91. Liu D, Zhang XL, Yan CH, Li Y, Tian XX, Zhu N, Rong JJ, Peng CF, Han YL (2014) MicroRNA-495 regulates the proliferation and apoptosis of human umbilical vein endothelial cells by targeting chemokine CCL2. Thromb Res. doi: 10.1016/j.thromres.2014.10.027
92. Weber KS, Nelson PJ, Grone HJ, Weber C (1999) Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol 19(9):2085-2093
93. Kawano S, Nakamachi Y (2011) miR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis. Ann Rheum Dis 70(Suppl 1):i88-i91. doi: 10.1136/ard.2010.138669
94. Tano N, Kim HW, Ashraf M (2011) microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS ONE 6(10):e23114. doi: 10.1371/journal.pone.0023114
95. Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D, Delgado-Olguin P, Cybulsky MI, Fish JE (2013) MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 5(7):949-966. doi: 10.1002/emmm.201202318
96. Fan W, Fang R, Wu X, Liu J, Feng M, Dai G, Chen G, Wu G (2014) Shear-sensitive microRNA-34a modulates flow-dependent regulation of endothelial inflammation. J Cell Sci. doi: 10.1242/jcs.154252
97. Liao YC, Wang YS, Guo YC, Lin WL, Chang MH, Juo SH (2014) Let-7g improves multiple endothelial functions through targeting transforming growth factor-beta and SIRT-1 signaling. J Am Coll Cardiol 63(16):1685-1694. doi: 10.1016/j.jacc.2013.09.069
98. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P (2005) Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 115(9):2508-2516. doi: 10.1172/JCI24403
99. Zhu N, Zhang D, Chen S, Liu X, Lin L, Huang X, Guo Z, Liu J, Wang Y, Yuan W, Qin Y (2011) Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis 215(2):286-293. doi: 10.1016/j.atherosclerosis.2010.12.024
100. Barish GD, Yu RT, Karunasiri M, Ocampo CB, Dixon J, Benner C, Dent AL, Tangirala RK, Evans RM (2010) Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response. Genes Dev 24(24):2760-2765. doi: 10.1101/gad.1998010
101. Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai LJ, Leblanc M, Diehl C, Cerchietti L, Miller YI, Witztum JL, Melnick AM, Dent AL, Tangirala RK, Evans RM (2012) The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell Metab 15(4):554-562. doi: 10.1016/j.cmet.2012.02.012
102. Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalan-Campos J, Hartmann P, Thiemann A, Weber C, Schober A (2013) The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 127(15):1609-1619. doi: 10.1161/CIRCULATIONAHA.112.000736
103. Yang K, He YS, Wang XQ, Lu L, Chen QJ, Liu J, Sun Z, Shen WF (2011) MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett 585(6):854-860. doi: 10.1016/j.febslet.2011.02.009
104. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101(29):10679-10684. doi: 10.1073/pnas.0403249101
105. Tian GP, Tang YY, He PP, Lv YC, Ouyang XP, Zhao GJ, Tang SL, Wu JF, Wang JL, Peng J, Zhang M, Li Y, Cayabyab FS, Zheng XL, Zhang DW, Yin WD, Tang CK (2014) The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein E knockout mice. Biochem Biophys Res Commun 443(2):428-434. doi: 10.1016/j.bbrc.2013.11.109
106. Maegdefessel L, Spin JM, Raaz U, Eken SM, Toh R, Azuma J, Adam M, Nagakami F, Heymann HM, Chernugobova E, Jin H, Roy J, Hultgren R, Caidahl K, Schrepfer S, Hamsten A, Eriksson P, McConnell MV, Dalman RL, Tsao PS (2014) miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development. Nat Commun 5:5214. doi: 10.1038/ncomms6214
107. Kastrup J (2012) Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 217(5):483-491. doi: 10.1016/j.imbio.2011.04.007
108. Di Gregoli K, Jenkins N, Salter R, White S, Newby AC, Johnson JL (2014) MicroRNA-24 regulates macrophage behavior and retards atherosclerosis. Arterioscler Thromb Vasc Biol 34(9):1990-2000. doi: 10.1161/ATVBAHA.114.304088
109. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D, Fevgas A, Dalamagas T, Hatzigeorgiou AG (2015) DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res 43(database issue):D153-D159. doi: 10.1093/nar/gku1215